Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.1K
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

832
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
832
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

600
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
600
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

796
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
796
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

154
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
154
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Study of Multiparametric Renal MRI for CKD Progression (AFiRM).

Kidney international reports·2026
Same author

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
Same author

Fast segmentation with the NextBrain histological atlas.

Imaging neuroscience (Cambridge, Mass.)·2026
Same author

Real-Time, Inline Quantitative MRI Enabled by Scanner-Integrated Machine Learning: A Proof of Principle With NODDI.

Magnetic resonance in medicine·2026
Same author

The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.

European journal of nuclear medicine and molecular imaging·2026
Same author

Updated hepatitis D seroprevalence among HBsAg-positive persons aged ≥6 years in the United States, National Health and Nutrition Examination Survey, 2007‒2018.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Jan 5, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

9.0K

HIV and the liver.

Kenneth E Sherman1, Marion G Peters2, David L Thomas3

  • 1University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Topics in Antiviral Medicine
|October 22, 2019
PubMed
Summary
This summary is machine-generated.

Liver disease is a major health issue for people with HIV, with new causes like fatty liver disease emerging. Addressing barriers to care is crucial for managing liver conditions and preventing complications like liver cancer.

More Related Videos

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

10.5K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.8K

Related Experiment Videos

Last Updated: Jan 5, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

9.0K
Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

10.5K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.8K

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Liver disease is a significant cause of illness and death in people with human immunodeficiency virus (HIV).
  • Despite effective treatments for hepatitis C and B, liver disease causes persist and evolve.
  • Emerging etiologies include nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and hepatitis viruses A, D, and E.

Purpose of the Study:

  • To review the evolving landscape of liver disease in individuals with HIV.
  • To highlight new and persistent causes of liver disease in this population.
  • To discuss challenges in diagnosis and management.

Main Methods:

  • Literature review of current research on HIV and liver disease.
  • Analysis of epidemiological trends and etiological shifts.
  • Examination of treatment advancements and management barriers.

Main Results:

  • Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are increasingly prevalent.
  • Hepatitis viruses A, D, and E are emerging concerns.
  • Newer antiretroviral therapies may contribute to weight gain and fatty liver.
  • Hepatocellular carcinoma (HCC) is a growing complication, often diagnosed late.

Conclusions:

  • Liver disease in HIV is complex and multifactorial, requiring ongoing research and adapted clinical strategies.
  • Barriers such as cost, stigma, and mental health issues impede timely diagnosis and treatment.
  • Effective management necessitates a comprehensive approach addressing both viral and non-viral liver diseases and associated comorbidities.